About
Lucis is a preventive-health platform for individuals and employers that combines laboratory biomarker testing, wearable data, and AI-driven health guidance. Its differentiation is a broad, longitudinal view of health—covering more than 110 biomarkers across 11 body systems—paired with personalized action plans and clinical oversight.
Market
Lucis competes in Europe's consumer preventive-health, longevity, and digital-health market by turning recurring laboratory testing into actionable health management. It positions itself as a more accessible alternative to premium private longevity clinics and as a European analogue to Function Health, with membership pricing starting at €490 per year. Its differentiation is the combination of 110+ biomarkers, longitudinal wearable and lab data, AI-generated personalized protocols, clinical oversight, and a broad European laboratory network rather than one-off testing or generic wellness content.
Lucis primarily targets health-conscious adults aged 18+ in Europe who want recurring biomarker testing, clearer health guidance, improved energy/recovery, and longer-term preventive-health tracking. Its secondary customer is the employer—especially startups and growing companies—buying Lucis as a data-driven health benefit for employees.
At a Glance
Problem
Lucis addresses the gap between having health data and knowing what to do with it. Conventional blood testing can produce isolated measurements that are difficult for individuals to interpret or connect to longer-term trends, making preventive action feel reactive, fragmented, or inaccessible. The core use case is helping someone understand their underlying biology, identify what matters across multiple body systems, and make more informed health decisions before a problem becomes acute. Lucis explicitly positions itself as a health companion rather than a replacement for medical diagnosis or prescriptions.
Product / Service
Lucis is a paid preventive-health membership that combines blood biomarker analysis with an AI-powered platform delivering personalised, science-based recommendations. Its current offering is listed at €490 annually and includes blood, saliva, and urine testing, 110 markers in the first test, 60 in the second, coverage across 11 body systems, wearable integration, and access to laboratories across Europe. The platform translates test results into an ongoing, data-driven view of health, supported by clinician review tools and a network of physicians, so members can track trends and act on relevant changes rather than simply receive a laboratory report.
Market
Lucis competes in the European consumer preventive-health and predictive-health market, at the intersection of biomarker testing, digital health coaching, and personalised wellness. The available research does not identify named direct competitors, but Lucis’s positioning differentiates it from a one-off testing service by combining recurring testing, AI interpretation, longitudinal health tracking, and personalised recommendations. Its €490 annual price indicates a commercial subscription model rather than a purely pre-revenue concept.
The company launched in 2025 and, by May 2026, reported more than 10,000 users across France, the UK, Ireland, and Portugal. It also reported a $20 million Series A led by Singular, with participation from General Catalyst and Y Combinator, alongside a team of 20 and a growing network of more than 10 physicians. That combination of paid pricing, international users, institutional funding, and clinical infrastructure suggests meaningful early traction, although the available evidence does not provide revenue, retention, or outcome metrics.
Founders & Leadership
Funding History
Y Combinator
General Catalyst
Singular
Recent News
HealthTechDigital covered Lucis’s $20 million Series A and its plans to expand preventive healthcare across Europe, including Spain, Germany, and Italy by the end of 2026.
Lucis announced a $20 million Series A led by Singular, with participation from General Catalyst, Y Combinator, and angel investors. The funding will support European expansion and development of its AI-powered health companion app.
Lucis and teleconsultation provider Livi launched a digital preventive-care pathway combining analysis of 110 biomarkers, an AI-generated and physician-validated assessment, and preventive teleconsultations with trained practitioners.
Lucis became HYROX Toulouse’s official preparation and recovery partner. The collaboration supports HYROX athletes with biomarker assessments, personalized nutrition and recovery plans, follow-up testing, and a dedicated recovery booth.
Wellworthy reported on Lucis’s Outlive London week, scheduled for February 7–13, featuring blood work covering more than 100 biomarkers, contrast therapy, HIIT sessions, and other longevity-focused experiences.
General Catalyst announced that it was leading Lucis’s seed round to support the company’s mission of extending European healthspan. The investor described Lucis’s model of turning comprehensive blood tests into personalized preventive actions through a network of certified laboratories.
Tech.eu reported that Lucis closed an $8.5 million seed round led by General Catalyst to expand access to preventive health testing in Europe.
EU-Startups reported that Lucis raised €7.2 million ($8.5 million) in seed funding from General Catalyst, Y Combinator, and other investors to support its European expansion.
Active Roles
9Business Model
Lucis primarily sells annual consumer memberships priced at €490 per year (€41 per month), including recurring laboratory assessments, health insights, and personalized guidance. It also monetizes additional tests and offers annual workplace wellness assessments to companies.